|
Video: What is a Stock Split?
|
|
Harrow is an ophthalmic-focused pharmaceutical company. Co. engages in the development, production, sale and distribution of prescription medications. Co. owns and operates ImprimisRx, the ophthalmology-focused pharmaceutical-compounding business, and its branded drugs are marketed under its Harrow name. In addition, Co. also has non-controlling equity positions in Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures. According to our Harrow stock split history records, Harrow has had 0 splits. | |
|
Harrow (HROW) has 0 splits in our Harrow stock split history database.
Looking at the Harrow stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Harrow shares, starting with a $10,000 purchase of HROW, presented on a split-history-adjusted basis factoring in the complete Harrow stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$7.21 |
|
End price/share: |
$10.00 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
38.70% |
|
Average Annual Total Return: |
3.33% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$13,874.75 |
|
Years: |
10.00 |
|
|
|
|
|